307 related articles for article (PubMed ID: 10993223)
1. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
3. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
Miyake K; Hirayama F; Uekama K
J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical characterization of a new crystal form and improvements in the pharmaceutical properties of the poorly water-soluble antiosteoporosis drug 3,9-bis(N,N-dimethylcarbamoy-loxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) by solid dispersion with hydroxypropylcellulose.
Yamada T; Saito N; Anraku M; Imai T; Otagiri M
Pharm Dev Technol; 2000; 5(4):443-54. PubMed ID: 11109244
[TBL] [Abstract][Full Text] [Related]
5. [Polymorphism of 3,9-bis-(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2- c]quinoline-6-one(KCA-098), a new benzofuroquinoline derivative].
Yamada T; Ikegami K; Toda M; Saito N; Iizuka K; Otagiri M
Yakugaku Zasshi; 1995 Dec; 115(12):978-84. PubMed ID: 8587037
[TBL] [Abstract][Full Text] [Related]
6. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
Nakai Y; el-Said Aboutaleb A; Yamamoto K; Saleh SI; Ahmed MO
Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
[TBL] [Abstract][Full Text] [Related]
7. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
Hirayama F; Mieda S; Miyamoto Y; Arima H; Uekama K
J Pharm Sci; 1999 Oct; 88(10):970-5. PubMed ID: 10514341
[TBL] [Abstract][Full Text] [Related]
8. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
[TBL] [Abstract][Full Text] [Related]
9. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
Anzai K; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
[TBL] [Abstract][Full Text] [Related]
10. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
[TBL] [Abstract][Full Text] [Related]
12. Improvement of dissolution characteristics of psoralen by cyclodextrins complexation.
Vincieri FF; Mazzi G; Mulinacci N; Bambagiotti-Alberti M; Dall' Acqua F; Vedaldi D
Farmaco; 1995; 50(7-8):543-7. PubMed ID: 7669193
[TBL] [Abstract][Full Text] [Related]
13. Physical properties of the complexes formed between heptakis(2,6-di-O-methyl)-beta-cyclodextrin, beta-cyclodextrin, and chlorambucil.
Green AR; Miller ES; Guillory JK
J Pharm Sci; 1991 Feb; 80(2):186-9. PubMed ID: 2051328
[TBL] [Abstract][Full Text] [Related]
14. Study of the interaction of dithranol with heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin in solution and in the solid state.
Cafaggi S; Vallarino M; Caviglioli G; Parodi B; Bignardi G
J Pharm Pharmacol; 1998 Mar; 50(3):257-64. PubMed ID: 9600716
[TBL] [Abstract][Full Text] [Related]
15. Rofecoxib-beta-cyclodextrin inclusion complex for solubility enhancement.
Rawat S; Jain SK
Pharmazie; 2003 Sep; 58(9):639-41. PubMed ID: 14531460
[TBL] [Abstract][Full Text] [Related]
16. Improvement of the Ocular Bioavailability of Econazole Nitrate upon Complexation with Cyclodextrins.
Abd El-Gawad AEH; Soliman OA; El-Dahan MS; Al-Zuhairy SAS
AAPS PharmSciTech; 2017 Jul; 18(5):1795-1809. PubMed ID: 27830515
[TBL] [Abstract][Full Text] [Related]
17. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems.
Veiga F; Fernandes C; Maincent P
Drug Dev Ind Pharm; 2001 Jul; 27(6):523-32. PubMed ID: 11548859
[TBL] [Abstract][Full Text] [Related]
18. Physico-chemical characterization of disoxaril-dimethyl-beta-cyclodextrin inclusion complex and in vitro permeation studies.
Ventura CA; Giannone I; Musumeci T; Pignatello R; Ragni L; Landolfi C; Milanese C; Paolino D; Puglisi G
Eur J Med Chem; 2006 Feb; 41(2):233-40. PubMed ID: 16387393
[TBL] [Abstract][Full Text] [Related]
19. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
Mady FM; Farghaly Aly U
Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
[TBL] [Abstract][Full Text] [Related]
20. Preparation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization.
Hirayama F; Kurihara M; Horiuchi Y; Utsuki T; Uekama K; Yamasaki M
Pharm Res; 1993 Feb; 10(2):208-13. PubMed ID: 8384365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
